The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Linaclotide (Constella®) has been accepted for restricted use in the symptomatic treatment of moderate to severe irritable bowel syndrome with constipation (IBS-C) in adults. The restriction limits use to patients who have not responded adequately to or cannot tolerate all other suitable treatment options.
Saxagliptin and Metformin (Komboglyze®) has been accepted for restricted use to improve glycaemic control in adult patients aged 18 years and older with type 2 diabetes mellitus inadequately controlled on their maximally tolerated dose of metformin alone or those already being treated with the combination of saxagliptin and metformin as separate tablets. The restriction limits use to patient in whom the combination of saxagliptin and metformin is an appropriate choice and the addition of a sulphonylurea is considered inappropriate.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.